

90 Views | 11 CrossRef citations to date | 0 Altmetric

Editorial

The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate

Jeremie Guedj, Harel Dahari, Susan L Uprichard & Alan S Perelson

Pages 397-399 | Published online: 10 Jan 2014

Cite this article <https://doi.org/10.1586/17474124.2013.811050>

Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Full Article Figures & data References Citations Metrics

Reprints & Permissions

[Read this article](#)

Share

We Care About Your Privacy

We and our 880 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting I Accept enables tracking technologies to support the purposes shown under we and our partners process data to provide. Selecting Reject All or withdrawing your consent will disable them. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the Show Purposes link on the bottom of the webpage. Your choices will have effect within our Website. For more details, refer to our Privacy Policy. [Here](#)

We and our partners process data to provide:

Use precise geolocation data. Actively scan device

I Accept

Reject All

Show Purpose



The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate

Expert Rev. Gastroenterol. Hepatol. 7(5), 397–399 (2013)



Jeremie Guedj
INSERM, UMR 738, Université Paris Diderot, Sorbonne Paris Cité, Paris 75018, France



Harel Dahari
Division of Hepatology, Department of Medicine, Loyola University Medical Center, Maywood, IL 60153, USA and Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA



Susan L Uprichard
Division of Hepatology, Department of Medicine, Loyola University Medical Center, Maywood, IL 60153, USA



Alan S Perelson
Author for correspondence: Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM 87545, USA
Tel.: +1 505 667 6829
asp@lanl.gov

“We employed mathematical modeling to decipher the origin of the very rapid viral decline observed in the first hours following initiation of daclatasvir, a first-in-class NS5A inhibitor, where one dose of daclatasvir led to a 1000-fold decrease in viral levels within approximately 12 h.”

Chronic infection with hepatitis C virus (HCV) affects approximately 160 million people worldwide [1] and is the leading cause of cirrhosis, liver cancer and liver transplantation [2]. Until 2011, the standard of care in the western world was weekly injections of pegylated-interferon (peg-IFN)- α and daily oral ribavirin (RBV), but viral eradication was achieved in less than 50% in treatment-naïve HCV genotype 1 patients, the most prevalent genotype in western world [3].

Since the approval in 2011 of two protease inhibitors (PIs), telaprevir (TVR) and boceprevir, in combination with peg-IFN/RBV, the landscape of anti-HCV therapy has been rapidly changing. Dozens of direct antiviral agents targeting different stages of the viral lifecycle are currently in clinical development, holding the promise that a universal cure can be achieved. Although results from clinical trials, often obtained in small populations of highly selected patients, should be taken with caution, short, tolerable, pan-genotype and IFN-free regimens appear to be attainable within the next couple of years.

In this highly dynamical context, there has been an increasing appeal from the industry and academics to use viral kinetic

functions, such as the HCV nonstructural protein 5A. In a recent paper published in *Proceedings of the National Academy of Sciences* [5], we employed mathematical modeling to decipher the origin of the very rapid viral decline observed in the first hours following initiation of daclatasvir (DCV), a first-in-class NS5A inhibitor, where one dose of DCV led to a 1000-fold decrease in viral levels within approximately 12 h [6].

Hepatitis C viral dynamics, virion half-life & drug antiviral effectiveness

One of the most important results of viral kinetic modeling was to introduce the idea that viral load level observed in a patient reflects the balance between the antagonist processes of production and clearance of the virus. By blocking viral production from infected cells, the initiation of antiviral treatment disrupts this equilibrium and the clearance of the virus is no longer efficiently compensated. Thus, the rate of viral decline observed early after treatment initiation can be used to calculate the virus half-life. This basic idea was used by Neumann *et al.* to fit the viral decline observed during interferon therapy and to estimate the antiviral



Financ
Portio
Energy (C
AI07888
a consul
financial
financial
from the

ent of
(R56/R01-
on has been
ffiliations or
st in or
uscript apart

Related research

People also read

Recommended articles

Cited by
11

Information for

- Authors
- R&D professionals
- Editors
- Librarians
- Societies

Opportunities

- Reprints and e-prints
- Advertising solutions
- Accelerated publication
- Corporate

Keep up

Register to receive updates by email

 Sign up

- 
- 
- 
- 

Copyright

Accessibility

Registered
5 Howick Pl

Open access

- Overview
- Open journals
- Open Select
- Dove Medical Press
- F1000Research

Help and information

- Help and contact
- Newsroom
- All journals

